8GC8

Bruton's tyrosine kinase L528W mutant in complex with 5-(piperidin-1-yl)-3-{[4-(piperidin-4-yl)phenyl]amino}pyrazine-2-carboxamide


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.75 Å
  • R-Value Free: 0.223 
  • R-Value Work: 0.195 
  • R-Value Observed: 0.197 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history


Literature

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.

Montoya, S.Bourcier, J.Noviski, M.Lu, H.Thompson, M.C.Chirino, A.Jahn, J.Sondhi, A.K.Gajewski, S.Tan, Y.S.M.Yung, S.Urban, A.Wang, E.Han, C.Mi, X.Kim, W.J.Sievers, Q.Auger, P.Bousquet, H.Brathaban, N.Bravo, B.Gessner, M.Guiducci, C.Iuliano, J.N.Kane, T.Mukerji, R.Reddy, P.J.Powers, J.Sanchez Garcia de Los Rios, M.Ye, J.Barrientos Risso, C.Tsai, D.Pardo, G.Notti, R.Q.Pardo, A.Affer, M.Nawaratne, V.Totiger, T.M.Pena-Velasquez, C.Rhodes, J.M.Zelenetz, A.D.Alencar, A.Roeker, L.E.Mehta, S.Garippa, R.Linley, A.Soni, R.K.Skanland, S.S.Brown, R.J.Mato, A.R.Hansen, G.M.Abdel-Wahab, O.Taylor, J.

(2024) Science 383: eadi5798-eadi5798

  • DOI: https://doi.org/10.1126/science.adi5798
  • Primary Citation of Related Structures:  
    8GC7, 8GC8

  • PubMed Abstract: 

    Increasing use of covalent and noncovalent inhibitors of Bruton's tyrosine kinase (BTK) has elucidated a series of acquired drug-resistant BTK mutations in patients with B cell malignancies. Here we identify inhibitor resistance mutations in BTK with distinct enzymatic activities, including some that impair BTK enzymatic activity while imparting novel protein-protein interactions that sustain B cell receptor (BCR) signaling. Furthermore, we describe a clinical-stage BTK and IKZF1/3 degrader, NX-2127, that can bind and proteasomally degrade each mutant BTK proteoform, resulting in potent blockade of BCR signaling. Treatment of chronic lymphocytic leukemia with NX-2127 achieves >80% degradation of BTK in patients and demonstrates proof-of-concept therapeutic benefit. These data reveal an oncogenic scaffold function of mutant BTK that confers resistance across clinically approved BTK inhibitors but is overcome by BTK degradation in patients.


  • Organizational Affiliation

    Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Tyrosine-protein kinase BTK270Homo sapiensMutation(s): 1 
Gene Names: BTKAGMX1ATKBPK
EC: 2.7.10.2
UniProt & NIH Common Fund Data Resources
Find proteins for Q06187 (Homo sapiens)
Explore Q06187 
Go to UniProtKB:  Q06187
PHAROS:  Q06187
GTEx:  ENSG00000010671 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ06187
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.75 Å
  • R-Value Free: 0.223 
  • R-Value Work: 0.195 
  • R-Value Observed: 0.197 
  • Space Group: P 2 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 38.38α = 90
b = 72.4β = 90
c = 104.51γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
XDSdata reduction
XDSdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data

  • Released Date: 2024-01-31 
  • Deposition Author(s): Gajewski, S.

Funding OrganizationLocationGrant Number
Other private--

Revision History  (Full details and data files)

  • Version 1.0: 2024-01-31
    Type: Initial release
  • Version 1.1: 2024-02-14
    Changes: Database references
  • Version 1.2: 2024-02-21
    Changes: Database references